Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Clozapine(click to collapse)
1/4 selected
Clozapine
Clozaril
Second-Generation Antipsychotic
FDA-approved indications
- Treatment-resistant schizophrenia (failure of standard antipsychotic treatment)
- Reducing risk of recurrent suicidal behavior in schizophrenia/schizoaffective disorder
Off-label uses
- Bipolar disorder (treatment-resistant)
- Psychosis in Parkinson's disease
- Aggression in intellectual disability
MechanismAtypical Antipsychotic
Half-life12 hours
Decision GuideWhen to pick each / when to consider an alternative
Clozapine
Consider when
- Treatment-resistant schizophrenia — only antipsychotic with level-1 evidence for TRS; guideline-mandated after two adequate trials
- Suicidality in schizophrenia/schizoaffective — unique FDA indication for suicide risk reduction (InterSePT trial)
- EPS intolerance from prior agents — lowest akathisia and parkinsonism risk; near-zero TD incidence
- Failed two adequate antipsychotic trials — discontinuation worsens outcomes; long-term retention superior to all other SGAs
- +1 more
Consider an alternative when
- Cannot commit to ANC monitoring — REMS-required weekly initially, then biweekly/monthly; non-negotiable
- Active myocarditis or cardiomyopathy history — labeled myocarditis warning; potentially fatal; highest cardiotoxicity among SGAs
- Prior clozapine-induced agranulocytosis — contraindicated for rechallenge after severe neutropenia (ANC <500)
- Severe constipation or GI hypomotility risk — life-threatening ileus and bowel necrosis; GI monitoring required
- +1 more
| Axis | Clozapine SGA |
|---|---|
| Boxed Warnings | |
Agranulocytosis / severe neutropenia | |
Myocarditis / cardiomyopathy (boxed warning) | |
Cerebrovascular events (elderly w/ dementia) | |
| CNS | |
Sedation / somnolence | |
Activation / insomnia | |
Akathisia / EPS | |
Seizure risk | |
| Metabolic | |
Weight gain | |
Metabolic (glucose / lipids) | |
| Endocrine | |
Prolactin elevation | |
| Autonomic | |
Anticholinergic burden | |
Orthostatic hypotension | |
Sweating | |
Sialorrhea / hypersalivation | |
| Cardiac | |
Heart rate / tachycardia | |
| GI | |
Nausea / GI (general) | |
Constipation / GI hypomotility | |
| Hepatic | |
Liver enzymes / hepatotoxicity | |
| Sexual | |
Sexual dysfunction | |
| Discontinuation | |
Withdrawal / discontinuation | |
| Interactions | |
CYP interactions / DDI profile | |
| Pregnancy | |
Teratogenicity | |
Lactation / breastfeeding safety | |